Introduction
Alzheimer's disease is the most common age-related neurodegenerative disease. Alzheimer's disease progressively and profoundly affects the quality of life of patients and their families. The earliest indications of Alzheimer's disease are usually cognitive decline and memory deficits, which progress to diminishing functional ability, behavioural disturbances, absolute dependence on caregivers and, finally, death. The disease extracts a heavy toll, with greatly increased health-care costs and enormous caregiver resources required to care for these patients.
The cholinesterase inhibitors (ChEIs) tacrine, donepezil, rivastigmine and galantamine are approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer's disease in the mild to moderate stages. Tacrine, the first ChEI to be approved, is no longer in widespread clinical use because it is associated with an unacceptable degree of hepatotoxicity. 1 The N-methyl-D-aspartate (NMDA) receptor B Seltzer Alzheimer's disease management with cholinesterase inhibitors antagonist memantine is FDA-approved for the treatment of moderate to severe Alzheimer's disease. Memantine has been used by itself and in combination with ChEIs. ChEIs are considered the standard of care for patients with what is termed 'mild to moderate Alzheimer's disease' (Mini-Mental State Examination [MMSE] scores range from 10 to 26). Their efficacy and safety have been well established in numerous placebocontrolled and open-label studies ( Table 1) . 2 -11 Two important clinical lessons have emerged from this extensive experience. First, patients retain more of their cognitive and functional abilities the earlier they start treatment. Secondly, these abilities are best maintained by following a persistent, continuous course of treatment. These observations 
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suggest a practical strategy for treating Alzheimer's disease: improve recognition and diagnosis; treat early; and continue treatment without interruption for as long as possible.
Early initiation and the delayed-start penalty
Cholinesterase inhibitors are well studied in mild to moderate Alzheimer's disease. Compared with placebo, donepezil, rivastigmine and galantamine improved outcomes in measures of cognition, 2 -10 function, 2 -4,6 -10 activities of daily living 2, 9, 11 and behaviour 9 in trials ranging in length from 15 to 30 weeks. The first evidence that early treatment is advantageous was seen in open-label extensions of placebo-controlled studies. Patients who initially received placebo rather than active treatment achieved, on average, lower cognitive and functional levels when started on active treatment than patients who had received active treatment from the beginning of the study. 4, 12, 13 In the Nordic study, which comprised a 1-year double-blind phase followed by 2 years of open-label treatment, 14 patients treated continuously with donepezil for 3 years had less cognitive and functional decline than patients who had a 1-year delay to the start of treatment. 14 Similarly, in a 26-week open-label extension of a 26-week double-blind study of rivastigmine 13 and in a 6-month open-label extension of a 6-month double-blind trial with galantamine, 15 patients who received ChEIs throughout the study period had significantly better scores on the Alzheimer's Disease Assessment Scale -cognitive subscale (ADAS-cog) than did patients who had received placebo for the initial double-blind phase of the trial. These consistent observations support the initiation of treatment as early as possible and warrant the evaluation of ChEIs in early Alzheimer's disease.
Until now, clinical trials of the ChEIs have focused mainly on patients with mild to moderate Alzheimer's disease (MMSE score 10 -26) . At this stage of Alzheimer's disease it is clear that untreated patients will experience cognitive and functional decline over a 6-month period, but disease progression is much slower in the earliest stages of Alzheimer's disease. Can treatment in these early stages also provide noticeable value? One study 16 evaluated 153 patients in the earliest stage of Alzheimer's disease (MMSE score 20 -26) and found that although MMSE and ADAS-cog scores remained stationary over 6 months for placebo-treated patients, they improved significantly for donepezil-treated patients. These results suggest that ChEI treatment may significantly enhance cognition even when a significant rate of cognitive decline is not evident, and strongly suggest that patients in the earliest stages of Alzheimer's disease should be treated with ChEIs.
According to the cholinergic hypothesis, 17, 18 which is the rationale for treating Alzheimer's disease with ChEIs, these drugs exert a symptomatic benefit by compensating to some extent for a deficiency in central cholinergic neurotransmission. Such a deficiency might be conceived as a relatively late phenomenon in the pathophysiology of Alzheimer's disease. Basic science may, however, provide an explanation for the observed advantages of early treatment with ChEIs. Thus, recent studies show changes in markers of the cholinergic system in patients with early Alzheimer's disease 19 and mild cognitive impairment. 20 In addition, findings from in vivo imaging studies hint at possible noncholinergic effects of ChEIs that may influence the course of the disease. An in vivo imaging study 21 showed significant preservation of hippocampal volume associated with donepezil treatment over a 6-month period. The
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Alzheimer's disease management with cholinesterase inhibitors same study showed a significant, albeit transient, increase in N-acetylaspartate levels in certain other brain regions following treatment with donepezil but not with placebo. Brain levels of N-acetylaspartate, a marker of the functional and structural integrity of neurons, are known to be reduced in Alzheimer's disease. 22 In a separate study, donepezil treatment was associated with increased cortical blood flow compared with placebo. 23 In addition, functional brain imaging studies showed that treatment with donepezil and rivastigmine improved glucose metabolism relative to placebo. 24, 25 In vitro studies in cell cultures (rat cortical neurons and rat phaeochromocytoma cells) suggest that ChEIs may actually be neuroprotective, because the addition of a ChEI to the culture protects cells against damage induced by oxygen-glucose deprivation 26, 27 and glutamate-mediated cytotoxicity. 28 Proposed mechanisms for this effect include antagonist activity at NMDA receptor sites, 29 the induction of neuroprotective factors by the modulation of nicotinic acetylcholine receptors 28 and the modulation of gene expression. 26 Taken together, these findings suggest that the ChEIs may act via noncholinergic as well as cholinergic mechanisms, some of which may have the potential to modify the pathological course of Alzheimer's disease. More research is needed to determine whether these effects are clinically relevant.
Persistent treatment and long-term outcomes
Like cardiovascular disease and Parkinson's disease, Alzheimer's disease calls for longterm treatment strategies. Indeed, long-term treatment with ChEIs has been shown to stabilize or slow the decline in cognition. In a 1-year placebo-controlled trial, MMSE scores remained at or close to baseline for a group treated with donepezil, whereas those for the group receiving placebo deteriorated by 2.2 ± 0.5 points. 30 In open-label 144-week 12 and 254-week 31 studies, the rate of cognitive decline in a group treated with donepezil was substantially less than the annual decline in ADAS-cog scores reported in untreated historical control patients. 31 These data show that donepezil is a welltolerated, realistic symptomatic treatment for Alzheimer's disease over a period of up to 4.9 years. 31 Sustained cognitive benefits were also noted with galantamine in 12-month 4 and 36-month open-label trials. 32 A 52-week study of rivastigmine (26 weeks double-blind plus 26 weeks open-label) reported a 5.7-point difference in ADAS-cog scores in favour of rivastigmine-treated patients versus projected placebo. 13 Long-term studies with donepezil 12,33 and galantamine 4, 32 have also shown good safety and tolerability profiles; most common adverse events were associated with the digestive system and were generally mild and transient.
The effects of ChEIs on cognition translate to meaningful long-term maintenance of functional independence. A 1-year doubleblind, placebo-controlled trial specifically evaluated the effect of donepezil on the patients' ability to perform basic and instrumental activities of daily living. The primary efficacy measure was clinically evident functional decline, defined as a decline in the ability to perform one basic activity of daily living, a decline in the ability to perform at least 20% of instrumental activities of daily living, or an increase of 1 point or more on the Clinical Dementia Rating scale, 34 a global measure of dementia severity. Donepezil extended the median time to clinically evident functional decline by 5 months compared with placebo. 33 Although such rigorous functional evaluations have B Seltzer Alzheimer's disease management with cholinesterase inhibitors not been performed with other ChEIs, galantamine-treated patients showed less functional decline over a 12-month period versus the projected decline for patients initially receiving placebo. 4 Continuity of treatment is an important feature of a long-term Alzheimer's disease treatment plan because drug holidays or treatment gaps allow symptoms to rebound, sometimes irreversibly. In a 144-week extension of 15-week and 30-week double-blind, placebo-controlled trials of donepezil, a 3-week or 6-week washout period following the placebo-controlled phase resulted in loss of the improvements attained during the study period. 12 Treatment effects were regained only partially when therapy was subsequently resumed. Indeed, a washout period as short as 3 weeks diminished the long-term effects of donepezil treatment, although test scores remained above baseline values. In comparison, the 6-week washout cohort showed a complete loss of cognitive gains. 12 Because of these findings, the designs of later extension studies of galantamine and rivastigmine did not include washout periods. 13, 15 Overcoming barriers to early and persistent treatment Given the evidence that the most effective treatment strategies for Alzheimer's disease include early and persistent treatment, what practical changes can practitioners make to enable treatment to be initiated earlier in the disease course? The principal barrier to early treatment is missed or delayed diagnosis. Some investigators have suggested that more than 40% of dementia cases in primary care settings go undiagnosed. 35 Furthermore, patients may not seek a physician's advice for months or years after the onset of memory problems, by which time cognitive and functional symptoms have progressed further. Clearly, improved diagnosis would allow many patients to be treated more effectively.
A number of factors may contribute to delayed diagnosis in the primary care setting. Clinicians often report being uncomfortable making a diagnosis of dementia because of uncertainty as to where to draw the line between normal age-related changes in cognition and frank dementia. 36 Clinicians also sense that a patient's physical problems take precedence over cognitive ones. Time constraints, anosognosia (unawareness) on the part of the patient, and denial and embarrassment on the part of family members also limit thorough cognitive assessment during routine clinical visits. Finally, there remains an underlying scepticism regarding the importance of timely diagnosis and early initiation of treatment in the management of Alzheimer's disease.
A survey of primary care physicians identified the briefness of the time available to administer suitable tests as a critical factor in the problem of underdiagnosis. 37 Several simple and efficient cognitive tests or screening tools, such as the clock drawing test, 36 are now available for use in busy practices. Nurses, nurse practitioners and physician assistants may also be trained to administer these assessments. In many instances, one can elicit an impression of cognitive status without tests by simple conversation during the course of routine examination. The patient's inability to recall newsworthy/everyday events or to recount routine medication may provide diagnostic clues to the attentive clinician. 36 It is also very important to query family members, as they are often the first to recognize cognitive and behavioural changes. Because of embarrassment or denial, family members may not be forthcoming with this information unless prompted.
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Lack of objective milestones to indicate treatment success is a barrier to persistent treatment.
Although many patients experience short-term improvement in dementia symptoms when ChEI therapy is initiated, others are either stabilized at current levels or continue to decline, but more slowly than would be expected for untreated Alzheimer's disease. While there are several measures to evaluate treatment effects in patient cohorts in clinical trials, there is currently no standard clinical approach or recommended time frame to determine treatment success in the individual patient with Alzheimer's disease. In clinical practice, patients with Alzheimer's disease whose condition does not improve after 6 months of treatment are often discontinued from therapy. Findings from a recent study, however, suggest that initial decline is not necessarily indicative of a lack of treatment success over the long term. In a double-blind, placebo-controlled study enrolling patients who had shown an apparent lack of clinical benefit in 12 -24 weeks of open-label donepezil treatment, significant differences favouring donepezil were observed in cognition, behaviour and activities of daily living when patients were restarted on donepezil therapy. 38 Physicians should therefore be cautious when deciding whether to discontinue treatment, as patients may ultimately experience significant treatment benefits over a longer treatment period. 38 The MMSE score alone is not sufficient to determine the success or failure of treatment. The patient's ability to perform activities of daily living and the frequency and severity of problem behaviours should also be taken into account. Other outcomes, such as delaying nursing home placement, 39, 40 may be especially important to families. Treatment may also make the patient less demanding of the caregiver's time and resources. 41 -43 The decision to continue or cease treatment should therefore hinge not only on cognitive test scores but also on a global evaluation of the patient's and caregiver's function and well-being. For all these reasons it is always advisable, in the absence of significant adverse events or financial concerns, to maintain patients on ChEI therapy even if clinical improvement is not obvious. The clinician must, however, make the rationale for this approach clear to the patient and caregiver.
Whether treatment with a ChEI delays eventual placement in a nursing home or other facility remains controversial. In an observational study, Lopez et al. 40 found that after 3 years of follow-up only 6% of patients treated with ChEIs were admitted to nursing homes, compared with 40% of untreated patients. Observational follow-up of patients from three controlled trials of donepezil revealed that donepezil treatment delayed the first dementia-related nursing home placement by approximately 21 months and permanent nursing home placement by approximately 18 months. 39 A modelling study projecting data from two US clinical trials of galantamine predicted that galantamine-treated patients would spend an average of 19 -20 months in full-time care (either residential or community-based), compared with approximately 23 months for untreated patients. 44 While the 3-year placebo-controlled AD2000 study 45 purported to show no significant difference among donepezil-and placebo-treated patients in delay to nursing home placement, it must be noted that the study was underpowered to assess this outcome and only four patients entered the final stage of the study. Further studies will be required to understand better the therapeutic, social and economic benefits of ChEI therapy in the long-term management of Alzheimer's disease.

Summary and conclusions
Cholinesterase inhibitors have earned their central role in dementia therapy, with longterm effectiveness and substantial benefit to patients, families and caregivers. The extensive experience with these drugs reveals that they are most effective when started early and used persistently. Important barriers to early and persistent treatment include inadequate diagnosis of Alzheimer's disease and the difficulty of determining treatment success in individual patients. These barriers can be overcome by screening for Alzheimer's disease in primary care; considering the effect of treatment on cognitive, functional and behavioural domains; and making treatment decisions based on multiple sources of information, including the family members or caregivers who know the patient best.
